2022
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma
Shayeb A, McManus H, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan C, Barata P, Bilen M, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 21: 55-62. PMID: 36411184, DOI: 10.1016/j.clgc.2022.10.013.Peer-Reviewed Original ResearchConceptsLow molecular weight heparinRenal cell carcinomaMajor bleeding eventsBleeding eventsRecurrent VTECell carcinomaDirect oral anticoagulant useAdvanced renal cell carcinomaDifferent anticoagulantsPrimary safety endpointSafety of cabozantinibOral anticoagulant usePrimary efficacy endpointClear cell histologyReal-world cohortRetrospective multicenter studyRisk-benefit discussionsLimited safety dataVenous thromboembolism managementMolecular weight heparinAnticoagulant groupConcurrent anticoagulationDOAC groupThrombosis complicationsEfficacy endpoint
2021
Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).
Mesleh Shayeb A, Urman D, Dizman N, Meza L, Sivakumar A, Gan C, Dzimitrowicz H, Zhang T, Barata P, Bilen M, Gao X, Heng D, Pal S, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 291-291. DOI: 10.1200/jco.2021.39.6_suppl.291.Peer-Reviewed Original ResearchLow molecular weight heparinDirect oral anticoagulantsRenal cell carcinomaAdvanced renal cell carcinomaMajor bleeding eventsVenous thromboembolismBleeding eventsMajor bleedingSafety profileDifferent anticoagulantsSimilar bleeding riskRecurrent venous thromboembolismClear cell histologyRetrospective multicenter studyMolecular weight heparinCause of deathFisher's exact testLMWH useRCC outcomeBleeding riskMedian doseOral anticoagulantsPrimary endpointSecondary endpointsVTE events